博腾股份(300363) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 reached ¥801,157,840.81, representing an increase of 18.21% compared to ¥677,717,562.88 in the same period last year[5] - The net profit attributable to shareholders was a loss of ¥4,284,210.42, a significant improvement of 95.48% from a loss of ¥94,870,808.04 in the previous year[5] - The net cash flow from operating activities was ¥85,633,196.17, up by 4.89% from ¥81,640,179.27 year-on-year[5] - The company reported a basic earnings per share of -¥0.01, improving by 94.12% from -¥0.17 in the same period last year[5] - The net profit for the current period was a loss of ¥25,549,774.96, compared to a loss of ¥124,349,577.22 in the previous period, indicating an improvement in financial performance[22] - The total comprehensive income attributable to the parent company was 15,438,988.48, compared to a loss of 118,605,503.13 in the previous period[23] Revenue Breakdown - In Q1 2025, the company achieved a revenue of 801 million RMB, representing a year-on-year growth of approximately 18%[16] - Revenue from overseas customers reached 609 million RMB, a year-on-year increase of about 30%, while domestic market revenue was 192 million RMB, a decline of about 8%[16] - The small molecule API business generated 761 million RMB in revenue, reflecting a year-on-year growth of 20%[16] - The new business segment, including small molecule formulations, gene cell therapy, and new molecular business, collectively generated 40.59 million RMB, with a year-on-year decline of 4%[16] Asset and Liability Management - The total assets at the end of the reporting period were ¥8,652,923,500.15, a decrease of 1.85% from ¥8,816,154,536.24 at the end of the previous year[5] - Total liabilities decreased to ¥3,247,329,909.28 from ¥3,404,914,815.00, a reduction of about 4.6%[20] - The company's equity attributable to shareholders increased slightly to ¥5,213,559,588.70 from ¥5,198,043,040.95, showing a marginal growth of 0.3%[20] Cash Flow Analysis - The net cash flow from investing activities was -297,258,619.48, worsening from -194,253,284.08 in the previous period[25] - Cash and cash equivalents at the end of the period amounted to 1,230,014,954.40, down from 1,796,053,800.40 at the end of the previous period[25] - Cash inflows from operating activities totaled 860,882,498.96, up from 784,182,111.80 year-over-year[24] - The company received cash from the recovery of investments totaling 280,000,000.00 during the period[24] Cost Management - The company’s management expenses decreased by 24.69% to ¥89,433,766.87 from ¥118,748,944.04 in the previous year[9] - Total operating costs decreased to ¥810,265,983.07 from ¥815,918,162.41, showing a reduction of about 0.8%[22] - Research and development expenses were recorded at ¥72,899,412.82, down from ¥84,431,556.54, indicating a decrease of approximately 13.6%[22] - The company is focusing on improving operational efficiency and reducing costs, as evidenced by the decrease in total operating costs despite an increase in revenue[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 40,790, with the top ten shareholders holding a combined 45.28% of the shares[11] Government Support - The company reported a significant increase in government subsidies, contributing to other income of ¥10,088,952.51, up by 51.31% from ¥6,667,731.89 in the previous year[9]